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Abstract
Mutations in SLC34A1, encoding the proximal tubular sodium–phosphate
transporter NaPi-IIa, may cause a range of clinical phenotypes including
infantile hypercalcemia, a proximal renal Fanconi syndrome, which are typi-
cally autosomal recessive, and hypophosphatemic nephrolithiasis, which may
be an autosomal dominant trait. Here, we report two patients with mixed
clinical phenotypes, both with metabolic acidosis, hyperphosphaturia, and
renal stones. Patient A had a single heterozygous pathogenic missense muta-
tion (p.I456N) in SLC34A1, consistent with the autosomal dominant pattern
of renal stone disease in this family. Patient B, with an autosomal recessive
pattern of disease, was compound heterozygous for SLC34A1 variants; a mis-
sense variant (p.R512C) together with a relatively common in-frame deletion
p.V91A97del7 (91del7). Xenopus oocyte and renal (HKC-8) cell line transfec-
tion studies of the variants revealed limited cell surface localization, consistent
with trafficking defects. Co-expression of wild-type and I456N and 91del7
appeared to cause intracellular retention in HKC-8, whereas the R512C
mutant had a less dominant effect. Expression in Xenopus oocytes failed to
demonstrate a significant dominant negative effect for I456N and R512C;
however, a negative impact of 91del7 on [32P]phosphate transport was found.
In conclusion, we have investigated pathogenic alleles of SLC34A1 which con-
tribute to both autosomal dominant and autosomal recessive renal stone dis-
ease.
Introduction
The maintenance of plasma phosphate is an important
physiological function which requires an interplay
between intestinal absorption of phosphate, storage in the
bones, and excretion by the kidneys (Forster et al. 2011).
Only a small percentage of total body of phosphate is
present within the plasma; however, this is regulated
tightly by hormones including parathyroid hormone
(PTH), calcitriol, fibroblast growth factor 23 (iFGF-23),
and its cofactor klotho. Both iFGF-23 and klotho pro-
mote renal excretion of phosphate by regulation of proxi-
mal tubular phosphate transport proteins (Kuro and Moe
2017). Indeed, a set of renal proximal tubular phosphate
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transporters including the sodium–phosphate cotrans-
porters encoded by SLC34A1 and SLC34A3 allow for
reabsorption of 70–80% of filtered phosphate (Table 1).
The renal-specific sodium–phosphate cotransporter
encoded by SLC34A1 is termed NaPi-IIa and is located at
the apical brush border of the proximal tubule where it
allows reabsorption of filtered sodium and phosphate
(Sayer 2017).
Mutations in SLC34A1 are known to give several differ-
ent clinical disease phenotypes. These include an autoso-
mal recessive form of infantile hypercalcemia, where
biallelic mutations result in loss of function of NaPi-IIa
leading to phosphate depletion. This gives rise to a
decrease of iFGF-23 levels and results in an unrestricted
activation of 1,25-(OH)2D3 producing a phenotype of
hypercalcemia, hypercalciuria, and nephrocalcinosis (Sch-
lingmann et al. 2016; Wagner et al. 2017). Biallelic muta-
tions in SLC34A1 may also cause an autosomal recessive
Fanconi-like renotubular syndrome. A homozygous in-
frame 21-bp insertion duplication mutation
(p.I154_V160dup) was reported in a consanguineous fam-
ily where two affected siblings had a hypophosphatemic
rickets phenotype together with some signs of generalized
proximal tubulopathy (Magen et al. 2010).
In addition to these recessively inherited disease pheno-
types, autosomal dominant forms of disease have been
seen with single heterozygous changes in SLC34A1, nota-
bly hypophosphatemic nephrolithiasis/osteoporosis-1.
Two unrelated patients with biochemical hypophos-
phatemia and reduced renal phosphate reabsorption have
been reported (Prie et al. 2002). This included a man
with recurrent renal stones and a woman with evidence
of bone demineralization.
Murine models of SLC34A1 have been described.
Homozygous Slc34a1/ knockout mice demonstrated
increased urinary phosphate levels, hypophosphatemia,
and elevated 1,25-(OH)2D3 levels. Young animals exhib-
ited bony defects including poorly developed trabecular
bones and retarded secondary ossification which
improved with age (Beck et al. 1998). Heterozygous mice
were healthy but did have a mild biochemical phenotype.
Serum phosphate was normal, but the mice had evidence
of phosphaturia and had raised serum 1,25-(OH)2D3
levels (Beck et al. 1998).
Here, we present the clinical, genetic, and biochemical
data of two unrelated patients, in whom mutations in
SLC34A1 have resulted in different but overlapping phe-
notypes. We use in vitro modeling of the mutations to
determine their pathogenicity and contribution to loss of
renal phosphate handling.
Methods
Clinical, biochemical, and genetic analysis
Patients gave informed written consent to these studies.
Clinical data were reviewed. DNA was obtained from
patients and relatives where available. The study was
approved by the Newcastle upon Tyne Research Ethics
Committee. DNA was extracted from whole-blood sam-
ples. Next-generation sequencing of a renal stone panel
was performed as previously described (Halbritter et al.
2015), and variants/segregation was confirmed by Sanger
sequencing. In silico tools and database searches were
used to determine pathogenicity of variants and allele fre-
quency. Plasma levels of iFGF23 and 1,25(OH)2 vitamin
D3 were determined with an ELISA and radioimmunoas-
say kits, respectively (Immunotopics International, USA;
Immunodiagnostic System, Germany).
In silico modeling of SLC34A1 mutations
Mutations in SLC34A1 were modeled using a previously
reported NaPi-IIa homology model (Fenollar-Ferrer et al.
2014). Figures were prepared using PyMOL (http://www.
pymol.org/).
Molecular biology and expression studies
Site-directed mutagenesis was performed using the Quick-
change Lightning Kit (Agilent) and mutations were con-
firmed by sequencing. The open reading frames for green
Table 1. Summary of sodium–phosphate cotransporters type II in man.
Gene Protein Stoichiometry Phylogeny Tissue distribution Linked disorder
SLC34A1 NaPi-IIa 3 Na+/1 Pi electrogenic Mammals, vertebrates Renal proximal tubules Nephrocalcinosis
Infantile hypercalcemia
Fanconi renotubular syndrome
SLC34A2 NaPi-IIb 3 Na+/1 Pi electrogenic Mammals, vertebrates Small intestine, lungs,
testis, mammary
gland
Pulmonary alveolar microlithiasis
SLC34A3 NaPi-IIc 2 Na+/1 Pi electroneutral Mammals Renal proximal tubules Hypophosphatemic rickets with hypercalciuria
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fluorescent protein (GFP) and red fluorescent protein
(RFP) were introduced to the SLC34A1 sequence by over-
lapping PCR either at the 30 or 50 end. A plasmid for
transfection control (GFP alone) was generated by intro-
ducing a frame shift to the SLC34A1 open reading frame
immediately after the start codon. For oocyte injections,
plasmids were linearized using XbaI and in vitro tran-
scribed using the T7 mMessageMachine kit (Thermo-
Fisher).
Xenopus oocytes were purchased from Ecocyte (Ger-
many) and incubated in Barth’s solution. Routinely,
10 ng of in vitro synthesized RNA was injected, and [32P]
phosphate flux measurements were performed after 3–
5 days (Markovich 2008).
HKC-8 cells were cultured as previously described (Her-
nando et al. 2000). Cells were transfected with N-terminally
linked GFP/RFP-SLC34A1 constructs using Lipofectamine
2000 (ThermoFisher). Cell nuclei were stained with DAPI
and plasma membranes with either rhodamine-coupled
phalloidin or wheat germ agglutinin (WGA) (Vector Labo-
ratories) prior to imaging by confocal microscopy (Nikon
A1). Images were deconvolved (Huygens Professional) and
analyzed using NIS-Elements software (Nikon).
Preparation and analysis of urinary
exosomes
Urinary exosomes were collected from 15-mL urine by
serial centrifugation as previously reported (Pathare et al.
2018). The final pellet was resuspended in Laemmli buffer
(0.6% w/v SDS, 3% v/v glycerol, 18 mmol/L Tris-HCl pH
6.8, and 0.003% w/v bromophenol blue).
Case Reports
Patient A from the United Kingdom was referred to the
nephrology department at the age of 26 years for investi-
gation of raised serum alkaline phosphatase and low
serum phosphate. His medical history was noteworthy in
that the patient had sensorineural deafness, epilepsy,
learning difficulties, and renal impairment. There was an
autosomal dominant family history of renal stones, with
the patient’s mother being affected with recurrent calculi,
but no other clinical features. At the time of assessment,
he was not taking any medication and blood pressure was
normal (110/70 mmHg). Urine dipstick confirmed glyco-
suria (in the context of a normal blood glucose). Serum
and urine biochemistry initially showed hypophos-
phatemia and renal phosphate wasting which then nor-
malized in the context of progressive chronic kidney
disease (CKD) (Table 2). In the presence of CKD stage 4
(eGFR 23 mL/min/1.73 m2), serum iFGF23 levels were
raised and 1,25-(OH)2D3 were reduced. Renal ultrasound
scanning showed a single 7-mm calculus in the lower pole
of the left kidney and smaller calculi in the right kidney.
A screen for urinary amino acids revealed a generalized
aminoaciduria consistent with a proximal tubulopathy.
Genetic investigations using next-generation sequencing
of a targeted panel of renal stone genes revealed a single
heterozygous change in SLC34A1 (c.1367T>A; p.I456N)
which was confirmed by Sanger sequencing. There were
no pathogenic variants in the related phosphate trans-
porter SLC34A3. Segregation of the mutation from the
parents was not possible due to unavailability of DNA
samples; however, it is likely that the deafness, learning
difficulties, and epilepsy seen in the proband but not the
mother may be explained by another, as yet unidentified
cause. The patient was treated with phosphate and low-
dose vitamin D supplementation.
Patient B from Macedonia presented at 7 months of
age with severe hypophosphatemia and renal phosphate
wasting and a normal anion gap metabolic acidosis
(Table 2). The child was initially acutely unwell with
hypovolemia. Serum iFGF23 levels were raised and 1,25-
(OH)2D3 were reduced, which are not typical of NaPi-IIa
mutations and may reflect the clinical status of the
patient. Serum iFGF23 levels are reported to rise rapidly
in cases of sepsis and acute kidney injury. Renal ultra-
sound scanning revealed bilateral medullary nephrocalci-
nosis (Figure 1A) and metabolic acidosis (serum
bicarbonate 16 mmol/L). Serum iFGF23 levels were raised
and 1,25-(OH)2D3 were reduced. There was no other
family history of renal or stone disease. The patient was
managed with bicarbonate and phosphate supplementa-
tion. Genetic investigations (as above) revealed biallelic
mutations in SLC34A1 [c.1534C>T; p.R512C and
c.271_291del21; p.V91A97del7 (91del7)], which were con-
firmed by Sanger sequencing. The deletion segregated
from the paternal allele while the missense change segre-
gated from the mother.
In silico assessment of SLC34A1 variants
In silico analyses of the SLC34A1 variants are summarized
in Table 3. Variant c.1367T>A (I456N) has not been
reported previously and has a very low allele frequency in
the ExAC database. Variant c.1534C>T (R512C) is also
rare, whereas variant c.271_291del21 (91del7) is more
common. All mutations are predicted to be pathogenic
(Table 3), with the position of the I456N mutation, close
to the NaPi-IIa substrate binding pocket (Figure 1B–D),
consistent with a deleterious effect on transporter func-
tion. The NaP-IIa homology model, covering residues 97–
502 (Fenollar-Ferrer et al. 2014), did not allow for
insights as to the structure-function effects of the 91del7
and R512C mutations. However, previous reports suggest
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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that the 91del7 mutation affects protein trafficking
(Lapointe et al. 2006; Schlingmann et al. 2016). R512
(and I456) are evolutionarily highly conserved, indicative
of functional importance.
Functional characterization of SLC34A1
mutations
To determine the impact of the SLC34A1 mutations on
the function of NaPi-IIa, fluorescently labeled transporters
were expressed in Xenopus laevis oocytes and a renal
epithelial (HKC-8) cell line. NaPi-IIa mutants I456N,
R512C, and 91del7 exhibited significantly reduced [32P]
phosphate transport compared with wild-type NaPi-IIa
injected Xenopus oocytes (Figure 1E). As reported previ-
ously (Schlingmann et al. 2016), the 91del7 mutant
showed some residual activity when compared with
water-injected controls (Figure 1E). Fluorescence micro-
scopy confirmed membrane localization of wild-type
NaPi-IIa, and, to a lesser extent, the 91del7 mutant (Fig-
ure 1F). However, the I456N and R512C mutants failed
to reach the oocyte membrane.
To investigate the reduced membrane expression of
the missense variants I456N and R512C in a mammalian
model system, N-terminally tagged GFP and RFP con-
structs were expressed in HKC-8 cells (Figure 2A and
B). In HKC-8 cells, wild-type (WT) NaPi-IIa showed
predominantly apical localization with some residual
punctate intracellular staining in the subapical region
(Figure 2A). All the mutants showed predominantly
intracellular staining and protein accumulation in perin-
uclear compartments, indicating defective protein folding
and/or trafficking to the plasma membrane. A NaPi-IIa
construct (FS) with a premature termination codon
showed a homogenous fluorescence without clusters,
reminiscent of cytoplasmic GFP staining (Figure 2B,
bottom).
To test potential interactions between mutated and
wild-type transporters, co-expression experiments were
performed. Co-transfections of RFP-tagged mutated
SLC34A1 constructs (91del7, I456N, and R512C) with
GFP-tagged wild-type NaP-IIa resulted in much of the
protein being retained intracellularly in perinuclear, gran-
ular structures containing wild-type and mutated trans-
porters. Some of the wild-type transporters fail to reach
the periphery, suggesting a negative effect, of the mutated
forms on wild-type protein sorting (Figure 2B). The com-
plex nature of the efficient membrane delivery was also
confirmed when WT and mutated constructs were
assessed in Xenopus oocytes. Increasing amounts of WT
RNA (2.5–10 ng) concomitantly increased [32P]phosphate
transport, and transport activity was not influenced by
Figure 1. Clinical, structural, and functional characterization of SLC34A1 mutations. (A) Medullary nephrocalcinosis seen in patient B. Renal
ultrasound images of left and right kidneys are shown, demonstrating bilateral nephrocalcinosis. (B, C, D) Homology model of NaPi-IIa (residues
97–502) with the two structural repeats (RU1 and RU2) highlighted in green and cyan, respectively. Bound phosphate (Pi) is shown as orange
and red spheres and sodium ions as magenta spheres. Note that only approximate positions of the 91del7 and R512C mutants are indicated.
The hydrophobic isoleucine at position 456 (I456) in RU2 of wild-type NaPi-IIa (C) is replaced in (D) by the polar asparagine residue (I456N). (E)
Xenopus oocyte transport activity of wild-type (WT) and mutated SLC34A1-GFP-coupled constructs. Transport activity was determined by [32P]
phosphate flux measurements. WT significantly stimulates [32P]phosphate uptake compared with non-injected oocytes (P < 0.01, ANOVA post
hoc Tukey). The slightly increased transport rate with the mutants is not significant. (B) Surface expression of SLC34A1-GFP constructs in
Xenopus oocytes assessed by fluorescence microscopy. Fluorescence was quantified using image J, the average intensity of eight oocytes is
shown (range 0–255 AU).
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the C-terminal GFP or RFP tag (Figure 2C). Co-expres-
sion of 5 ng WT RNA with equal amounts of I456N
or R512C mutant RNA failed to significantly reduce
[32P]phosphate transport activity. However, co-expression
of WT and 91del7 RNAs caused some reduction in
[32P]phosphate transport (Figure 2D). Finally, urine-
derived exosomes were obtained from patient A, and
these confirmed the presence of NaPi-IIa detected by
Western blotting, consistent with a negative but not fully
dominant effect of the heterozygous p.I456N missense
variant (Figure 2E).
Discussion
The continued investigation of potential pathogenic alleles
in SLC34A1, which encodes the renal sodium–phosphate
transporter NaPi-IIa, is important in determining the role
of NaPi-IIa in proximal tubular function. Here, we
demonstrate clinical phenotypes occurring in both domi-
nant and recessive patterns. Autosomal dominant variants
in SLC34A1 are important to study, given that previous
reports of phenotypes are rare and are limited to renal
stone phenotypes and bone mineralization defects (Prie
et al. 2002; Braun et al. 2016). There is a clear role for
NaPi-IIa in proximal renal tubular phosphate reabsorp-
tion and mutations in SLC34A1 leading to renal stones
(Sayer 2017). Previous studies of cohorts of pediatric
stone formers have identified single heterozygous variants
in genes, including SLC34A1, associated with autosomal
dominant inheritance patterns (Braun et al. 2016). In this
cohort, 5 of 143 individuals (3.5%) had heterozygous
SLC34A1 variants associated with nephrolithiasis. How-
ever, the possible dominant negative effects of a heterozy-
gous mutation in SLC34A1 on other proximal renal
tubular transporters, producing a renal Fanconi syn-
drome, is harder to explain. Given the extra-renal mani-
festations in patient A and the atypical clinical course,
other underlying genetic changes may be implicated in
the overall phenotype. The SLC34A1 missense mutation
I456N we report here is novel and our data point toward
Table 2. Clinical, imaging, and biochemical features of patients.
Patient
A (UK)
Patient B
(Macedonia)
Age (years) 48 1
Renal imaging Bilateral
radiopaque
calculi
Bilateral medullary
nephrocalcinosis
Plasma phosphate
(mmol/L)
0.7–1.2 (↓-↔) 0.52 (↓)
Plasma bicarbonate
(mmol/L)
17 20
Plasma calcium
(mmol/L)
2.1 (↔) 2.1 (↔)
Plasma creatinine
(lmol/L)
265 (↑) 36(↔)
eGFR (mL/min/
1.73 m2)
23 (CKD-EPI) 66 (New Schwartz
formula)
Total Vitamin D
(nmol/L)
89 N/A
1,25-(OH)2 D3
(pg/mL)
30 (↓) 24 (↓)
iFGF23 (ng/L) 380 (↑) 152 (↑)
Urine pH 7.0 5.5
Urine calcium/
creatinine ratio
(mmol/mmol creatinine)
0.315(↔) 0.42(↔)
Fractional excretion of
phosphate (NR 10–20%)
79% (↑) 49% (↑)
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration for-
mula for estimating GFR; eGFR, estimated glomerular filtration
rate; N/A, not available; NR, normal range.
Table 3. In silico assessment of SLC34A1 mutations.
Nucleotide
change (Ref
sequence
NM_003052)
Amino
acid
change
Amino acid
conservation MutationTaster PolyPhen2 SIFT
ExAC
frequency References
c.1367T>A I456N To nematode1 Disease causing Probably
damaging
Deleterious 3 het alleles in 119,548
alleles
Novel
c.1534C>T R512C To nematode1 Disease causing Possibly
damaging
Deleterious 8 het alleles in 121,334
alleles
Halbritter et al. (2015)
c.271_291del21 91del7 n/a Disease causing n/a n/a 17 hom alleles and 2148
het alleles in
121,274 alleles
Lapointe et al. (2006)
and Schlingmann et al.
(2016)
Het, heterozygous; hom, homozygous.
1
GenBank accession KRZ90293.1
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a trafficking defect, consistent with the putative proximity
of the mutation to the functionally critical substrate-bind-
ing domain and is consistent with the proximal tubulopa-
thy phenotype we describe.
Both patients reported in this study exemplify the com-
plex consequences of mutations in SLC34A1 and the chal-
lenges characterizing them experimentally. Large-scale
genome sequencing projects, in combination with match-
ing patient data, point to a significant role of the genetic
background in mitigating phenotypic penetrance of delete-
rious SLC34A1 mutations (Xue et al. 2012). Mutations in
SLC34A1 show more severe and early-onset phenotypic
consequences if both alleles are affected. Accordingly,
patient B presented with severely disturbed phosphate
NaPi-IIa
GFP GFP GFP RFP
A
C D E
B
Figure 2. jeeFunctional assessment of SLC34A1 mutations in vitro and phenotyping of urinary exosomes. (A–B) Assessment of transfected
SLC34A1 constructs in HKC-8 cells. (A) Immunofluorescence images (subapical xy sections as well as xz and yz sections) of N-terminal GFP
transfected SLC34A1 constructs (green) and wheat germ agglutinin lectin membrane staining (WGA, red). The wild-type (WT) and mutant
SLC34A1 constructs (91del7, I456N, R512C) used are indicated. The white line indicates the cross-section. Scale bar 5 lm. (B) Co-transfections of
WT GFP-SLC34A1 construct (first column, specified at the left of each panel) and N-terminal RFP-SLC34A1 mutant constructs (middle column) and
overlay. Bottom row shows a GFP SLC34A1 construct with a frame shift after the start codon (FS) as transfection control and WGA staining (red).
Scale bar 5 lm. (C–D) Co-expression of WT and mutated SLC34A1 in Xenopus oocytes. (C) Dose–response measurements. Amount (ng) of injected
GFP or RFP-tagged SLC34A1 RNA are shown. (D) Co-injection of 5 ng of WT with the same quantity of mutated SLC34A1 RNA. (E) Western blot of
exosomes isolated from human and mouse urine. Control used urine from an aged-matched healthy human. Mouse 1 and 2 are healthy controls,
KO are murine knockout (null allele) for NaPi-IIa. Blots were probed with a polyclonal NaPi-IIa-specific antiserum that recognizes both human and
mouse isoforms (75–80 kDa). Samples were loaded to match serum creatinine levels. Beta-actin (42 kDa) was used as a loading control.
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balance before the age of 1 carrying two mutated SLC34A1
alleles (91del7 and R512C). We found that both mutations
significantly reduce phosphate transport in oocytes. A sig-
nificant variability between cells suggests dosage effects and
a strong influence of genetic/cellular background on the
phenotype. Intercellular variability may also explain the
discrepancy of our findings to Schlingmann et al. (2016)
who analyzed the 91del7 mutation and found normal
transport but impaired apical sorting in OK cells.
We tested whether dominant effects of single mutations
could be recapitulated using Xenopus oocytes and a renal
cell line. In oocytes, there was a slight but not significant
decrease in transport upon co-injection of WT and
I456N/R512C RNA, whereas co-expression of 91del7 with
WT caused a reduction in WT-induced transport. More-
over, all of the mutations appear to have a negative effect
on the sorting of the wild-type transporter. The fact that
the 91del7 mutation is found in about 2% of the popula-
tion (Wagner et al. 2017) may emphasize the importance
of the cellular background on the penetrance of a particu-
lar mutant.
To conclude, we report two patients with mutations in
SLC34A1 with severely affected phosphate homeostasis.
Characterization of the mutations confirms the deleteri-
ous effect on function and membrane delivery and points
to a yet uncharacterized contribution of the genetic/cellu-
lar background to the penetrance of the phenotype.
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